Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT

Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT

It is unclear whether the presence of albuminuria modifies the effects of intensive systolic BP control on risk of eGFR decline, cardiovascular events, or mortality. The Systolic Blood Pressure Intervention Trial randomized nondiabetic adults ≥50 years of age at high cardiovascular risk to a systoli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical journal of the American Society of Nephrology 2020-08, Vol.15 (8), p.1121-1128
Hauptverfasser: Chang, Alex R, Kramer, Holly, Wei, Guo, Boucher, Robert, Grams, Morgan E, Berlowitz, Dan, Bhatt, Udayan, Cohen, Debbie L, Drawz, Paul, Punzi, Henry, Freedman, Barry I, Haley, William, Hawfield, Amret, Horwitz, Edward, McLouth, Christopher, Morisky, Don, Papademetriou, Vasilios, Rocco, Michael V, Wall, Barry, Weiner, Daniel E, Zias, Athena, Beddhu, Srinivasan
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Albuminuria - diagnosis
Albuminuria - epidemiology
Albuminuria - mortality
Albuminuria - physiopathology
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Blood Pressure - drug effects
Female
Glomerular Filtration Rate
Humans
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - mortality
Hypertension - physiopathology
Incidence
Kidney - physiopathology
Kidney Diseases - diagnosis
Kidney Diseases - epidemiology
Kidney Diseases - mortality
Kidney Diseases - physiopathology
Male
Middle Aged
Time Factors
Treatment Outcome
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It is unclear whether the presence of albuminuria modifies the effects of intensive systolic BP control on risk of eGFR decline, cardiovascular events, or mortality. The Systolic Blood Pressure Intervention Trial randomized nondiabetic adults ≥50 years of age at high cardiovascular risk to a systolic BP target of
ISSN:1555-9041
1555-905X
DOI:10.2215/CJN.12371019